Clinical trials: Regorafenib
Gastrointestinal Stromal Tumors
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)
The purpose of this Managed Access Program is to provide regorafenib to patients diagnosed with metastatic and / or unresectable GIST who have progressed after standard therapy.
- Trial name
- NCT01689376
- Testing
- Regorafenib (BAY73-4506)
- Sponsor
- Bayer
Gastrointestinal Stromal Tumors
Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST
Evaluate the treatment with regorafenib in patients with metastatic and/or unresectable KIT/PDGFR wild type GIST in the first line setting.
- Trial name
- REGISTRI (NCT02638766)
- Testing
- regorafenib
- Where
- 17 sites in France, Italy and 1 more
- Volunteers
- 15 people
- Sponsor
- Grupo Espanol de Investigacion en Sarcomas
Neoplasms
Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer
Phase I: Determine the maximum tolerated dose of combination of Regorafenib with Refametinib through a dose escalation study, all tumor types that meet certain inclusion/exclusion criteria can be entered.
- Trial name
- NCT02168777
- Testing
- Refametinib (BAY86-9766), Regorafenib (Stivarga, BAY73-4506)
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Bayer
Glioblastoma Multiforme
Regorafenib in Relapsed Glioblastoma
This study aims to evaluate the role of Regorafenib in prolonging the overall survival of glioblastoma multiforme patients who progressed after surgery and Stupp regimen with or without bevacizumab.
- Trial name
- REGOMA (NCT02926222)
- Testing
- Regorafenib, Lomustine
- Where
- 10 sites in Italy
- Volunteers
- 119 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Colorectal Cancer, Liver Metastases
Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer
Research has found that patients with microsatellite instability (dMMR/MSI-H) type colorectal cancer can achieve long-term survival through immune checkpoint inhibitors (ICIs) treatment, but currently accounting for about 95% of…
- Conditions
- Colorectal Cancer, Liver Metastases, MSS
- Trial name
- REGOTORICOX (NCT05933980)
- Testing
- Rego+Tori+Cele
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
A Real World Study of Regogfinib in HCC
This is a non-interventional observational study with the primary objective of assessing the efficacy of regorafenib in patients with immediate or advanced stage HCC.
- Trial name
- NCT05557656
- Testing
- Regorafenib 40 MG
- Volunteers
- 800 people
- Sponsor
- Zhongda Hospital
Colorectal Cancer, Colorectal Tumors
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
The purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.
- Conditions
- Colorectal Cancer, Colorectal Tumors, Colorectal Carcinoma, Colorectal Neoplasm
- Trial name
- CheckMate 9N9 (NCT03377361)
- Testing
- Nivolumab, Trametinib, Ipilimumab
- Where
- 47 sites in United States, Argentina and 8 more
- Volunteers
- 325 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer, Colorectal Cancer Metastatic
Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
This phase I/II studies the side effects and best dose of regorafenib when given together with pembrolizumab in treating participants with colorectal cancer that has spread to other places in the body.
- Trial name
- NCT03657641
- Testing
- Pembrolizumab, Regorafenib
- Where
- 3 sites in United States
- Volunteers
- 73 people
- Sponsor
- University of Southern California
Ewing Sarcomas, Chondrosarcomas
A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
INDICATION: Metastatic bone sarcomas: conventional high grade osteosarcoma, Ewing sarcoma of bone, intermediate or high-grade chondrosarcomas and chordomas and either bone or soft tissue metastatic CIC-rearranged sarcomas
- Conditions
- Ewing Sarcomas, Chondrosarcomas, Osteosarcomas, Chondroma
- Trial name
- REGOBONE (NCT02389244)
- Testing
- Regorafenib
- Where
- 19 sites in France
- Volunteers
- 163 people
- Sponsor
- UNICANCER
Metastatic Colorectal Cancer
Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer
A randomized, phase II study comparing the sequences of regorafenib and trifluridine/tipiracil, after failure of standard therapies in patients with metastatic colorectal cancer
- Trial name
- SOREGATT (NCT04450836)
- Testing
- Regorafenib then Trifluridine/Tipiracil, Trifluridine/Tipiracil then Regorafenib
- Where
- 36 sites in Belgium, France
- Volunteers
- 234 people
- Sponsor
- UNICANCER
GIST
Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients
The aim of this study is to evaluate the safety and efficacy of lenvatinib in patients with metastatic or advanced GIST who have failed at least imatinib, sunitinib, and regorafenib treatment.
- Trial name
- LONGIST (NCT07096609)
- Testing
- Lenvatinib Capsules
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Asan Medical Center
Pancreatic Cancer Metastatic
A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer
The purpose of this clinical trial is to explore the efficacy and safety of Regorafenib combined with Toripalimab and Paclitaxel-albumin in patients as the third line treatment for patients with unresectable or metastatic…
- Trial name
- NCT07040228
- Testing
- Regorafenib combined with Toripalimab and Albumin paclitaxel
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Junjie Hang
Rhabdomyosarcoma
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS)
- Trial name
- FaR-RMS (NCT04625907)
- Testing
- Irinotecan, Actinomycin D, Doxorubicin
- Where
- 128 sites in Australia, Austria and 18 more
- Volunteers
- 1,672 people
- Sponsor
- University of Birmingham
Colorectal Neoplasms
Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
The purpose of this study is to assess the safety and efficacy of lenvatinib (MK-7902/E7080) in combination with pembrolizumab (MK-3475) in participants with metastatic colorectal cancer.
- Trial name
- NCT04776148
- Testing
- pembrolizumab, lenvatinib, regorafenib
- Where
- 95 sites in United States, Argentina and 13 more
- Volunteers
- 563 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Liver Metastasis
Hepatic Arterial Infusion Chemotherapy Combined With Sintilimab and Regorafenib as Adjuvant Therapy for Colorectal Liver Metastasis Patients With a High Risk of Recurrent: a Single-arm, Phase II Study
Pts with histologically confirmed CRLM and whose CRS >2 were enrolled into this single-arm, phase II study. The critical enrollment criteria were that Subjects had completely resected Primary lesion and liver metastases and had…
- Trial name
- NCT05753163
- Testing
- HAIC-FOLFOX combined with Sintilimab and Regorafenib
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Fudan University
Gastrointestinal Stromal Tumour (GIST)
Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation
The main purpose of this study is to examine whether regorafenib treatment can help people with gastrointestinal stromal tumours (GIST) and have gene mutation on c-kit exon 17. The safety of regorafenib treatment is also examined.
- Trial name
- NCT02606097
- Testing
- regorafenib
- Where
- Taiwan
- Volunteers
- 19 people
- Sponsor
- Chang Gung Memorial Hospital
Colorectal Cancer; Lung Cancer
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
- Trial name
- NCT04701476
- Testing
- TATE and pembrolizumab, TAS-102 pill, Regorafenib Pill
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 110 people
- Sponsor
- Teclison Ltd.
Metastatic Colorectal Cancer (mCRC), Colorectal Neoplasms
Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes
This study will evaluate efficacy and safety of hydroxychloroquine combined with methotrexate, capecitabine and bevacizumab versus regorafenib in participants with refractory metastatic colorectal cancer with mutations in KRAS or…
- Trial name
- x-МАР (NCT06949982)
- Testing
- experimental group x-MAP, Regorafenib (BAY 73-4506)
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- Sergey Orlov, MD
DC-CIK Treatment, Regorafenib
Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.
Research background and purpose: Patients with advanced colorectal cancer face the dilemma of limited treatment options and poor efficacy in the third line treatment stage.
- Conditions
- DC-CIK Treatment, Regorafenib, Colorectal Cancer, Immune Combination Therapy
- Trial name
- NCT07343791
- Testing
- DC-CIK combined with regorafenib ,Iparomlimab and Tuvonralimab Injection
- Where
- China
- Volunteers
- 14 people
- Sponsor
- JIANG LONGWEI
Hepatocellular Carcinoma
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
The primary goal of this study is to gather efficacy data concerning the progression-free survival rate with electromagnetic fields plus Regorafenib when compared to historical data with Regorafenib alone as a second-line therapy…
- Trial name
- NCT04327700
- Testing
- TheraBionic, Regorafenib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Wake Forest University Health Sciences